CompanyGraph
Crism Therapeutics Corporation
CRTX · British Virgin Islands
crismtherapeutics.comFinancials as of FY2024 · latest on file
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $10.16M, lower than 95% of all stocks globally
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
7.52MGBP10.16M · vs all stocks (USD)
Revenue (TTM)
231.00KGBP311.97K · vs all stocks (USD)
Beta
0.5990xvs all stocks
52-Week Change
-6.98%vs all stocks
Market Capitalization
7.52MGBP10.16M · vs all stocks (USD)
Enterprise Value
2.70MGBP3.64M · vs all stocks (USD)
Price to Sales (TTM)
32.57xvs Biotechnology peers
Price to Book (MRQ)
2.71xvs Biotechnology peers
Enterprise to Revenue
11.67xvs Biotechnology peers
Enterprise to EBITDA
-1.45xvs Biotechnology peers
Operating Margin
-419.91%vs Biotechnology peers
Return on Assets (TTM)
-64.97%vs Biotechnology peers
Return on Equity (TTM)
-129.78%vs Biotechnology peers
Revenue (TTM)
231.00KGBP311.97K · vs all stocks (USD)
Revenue per Share (TTM)
0.0060GBPUpdated Jul 28, 2026Gross Profit (TTM)
131.00KGBP176.92K · vs all stocks (USD)
EBITDA (TTM)
-1.86MGBP-2.51M · vs all stocks (USD)
Net Income (TTM)
-1.88MGBP-2.53M · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.97MGBP-2.66M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.27MGBP-1.71M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
33.61KUSDFY2024 · Dec 31, 2024Cost of Goods Sold
5.38KUSDFY2024 · Dec 31, 2024Gross Profit
28.24KUSDFY2024 · Dec 31, 2024Operating Income
-1.18MUSDvs all stocks (USD)
Pre-tax Income
-797.34KUSDFY2024 · Dec 31, 2024Income Tax Expense
0.00USDFY2024 · Dec 31, 2024Net Income
-816.16KUSDFY2024 · Dec 31, 2024EBIT
-782.54KUSDFY2024 · Dec 31, 2024EBITDA (Income Statement)
-1.16MUSDFY2024 · Dec 31, 2024Research & Development
225.89KUSDFY2024 · Dec 31, 2024Selling, General & Administrative
688.42KUSDFY2024 · Dec 31, 2024Non-operating Interest Expense
14.79KUSDFY2024 · Dec 31, 2024EPS (Basic)
-0.0180USDFY2024 · Dec 31, 2024EPS (Diluted)
-0.0180USDFY2024 · Dec 31, 2024Basic Shares Outstanding
43.27MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
43.27MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-816.16KUSDFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00USDFY2024 · Dec 31, 2024Operating Cash Flow
-1.27MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
1.69MUSDFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-800.91KUSDFY2024 · Dec 31, 2024Other Non-cash Items
14.51KUSDFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-484.24KUSDFY2024 · Dec 31, 2024Net Intangibles (CF)
-36.94KUSDFY2024 · Dec 31, 2024Net Acquisitions
3.11MUSDFY2024 · Dec 31, 2024Net Investing Cash Flow
3.11MUSDFY2024 · Dec 31, 2024Common Dividends Paid
-62.01KUSDFY2024 · Dec 31, 2024Net Financing Cash Flow
72.57KUSDFY2024 · Dec 31, 2024Shares Outstanding
51.74MSharesUpdated Jul 28, 2026Float Shares
23.67MSharesUpdated Jul 28, 2026% Held by Insiders
32.53%vs all stocks
% Held by Institutions
11.87%vs all stocks
Total Cash (MRQ)
1.13MGBP1.52M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0280GBPUpdated Jul 28, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
4.35xvs Biotechnology peers
Book Value per Share (MRQ)
0.0350GBPUpdated Jul 28, 2026Total Assets
2.40MUSDvs all stocks (USD)
Total Current Assets
2.23MUSDFY2024 · Dec 31, 2024Total Liabilities
449.94KUSDFY2024 · Dec 31, 2024Total Non-current Assets
166.25KUSDFY2024 · Dec 31, 2024Total Non-current Liabilities
0.00USDFY2024 · Dec 31, 2024Total Current Liabilities
449.94KUSDFY2024 · Dec 31, 2024Cash
1.69MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents
1.69MUSDFY2024 · Dec 31, 2024Accounts Receivable
0.00USDFY2024 · Dec 31, 2024Accounts Payable
38.26KUSDFY2024 · Dec 31, 2024Short-term Debt
0.00USDFY2024 · Dec 31, 2024Long-term Debt
0.00USDFY2024 · Dec 31, 2024Common Stock (Book)
87.38MUSDFY2024 · Dec 31, 2024Retained Earnings
-1.59MUSDFY2024 · Dec 31, 2024Total Shareholders' Equity
1.95MUSDvs all stocks (USD)
52-Week Low
8.00GBXUpdated Jul 28, 202652-Week High
18.50GBXUpdated Jul 28, 202652-Week Change
-6.98%vs all stocks
Beta
0.5990xvs all stocks
50-Day MA
10.44GBXUpdated Jul 28, 2026200-Day MA
11.44GBXUpdated Jul 28, 2026Avg 10-Day Volume
292.13KSharesUpdated Jul 28, 2026Avg 30-Day Volume
261.76KSharesUpdated Jul 28, 2026Diluted EPS (TTM)
-0.0500GBPUpdated Jul 28, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $10.16M, lower than 95% of all stocks globallySignificant
Market cap (USD): 10,159,497.343Global P5: 269,387,740.27
Revenue is $311,972, lower than 95% of all stocks globallySignificant
Revenue (USD): 311,972.43Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cindrigo Holdings Limited
Tier 1ProductionApproval-Gated PipelineFlowRisk
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated